Workflow
华邦健康首季赚1.84亿中期拟分红2.97亿 经营现金流降66%有息负债93.84亿

Core Viewpoint - Huabang Health proposed an interim dividend despite reporting a net loss for the first time since 2001, raising concerns about its financial health and aggressive dividend policy [1][2][3]. Financial Performance - In Q1 2025, Huabang Health reported revenue of 2.821 billion yuan, a year-on-year decrease of 3.24%, while net profit attributable to shareholders was 184 million yuan, an increase of 18.50% [1][5]. - For the full year 2024, the company recorded revenue of 11.665 billion yuan, essentially flat compared to the previous year, but reported a net loss of 299 million yuan, a decline of 198.96% [1][13]. - The company’s operating cash flow for Q1 2025 was 38 million yuan, down 66.06% from 112 million yuan in the same period last year [10]. Dividend Policy - Huabang Health's controlling shareholder proposed a cash dividend of at least 1.5 yuan per 10 shares, totaling at least 297 million yuan, which is 1.61 times the company's Q1 net profit [1][16]. - The company has maintained a high dividend payout ratio over the past decade, with rates exceeding 100% in 2022 and 2023, but did not distribute dividends in 2024 due to losses [3][17][19]. Debt and Financial Health - As of March 2025, Huabang Health had cash and cash equivalents of 3.888 billion yuan and interest-bearing liabilities of 9.384 billion yuan, indicating significant debt levels [4][22]. - The company is facing scrutiny for its strategy of high dividends while accumulating debt, with a total debt of 9.384 billion yuan against a cash position that may not be sufficient to cover it [20][22].